INS and cancer: When further adjusted by age, gender, hypertension, hyperlipidemia, cerebral vascular disease, coronary artery disease, chronic kidney disease, diabetes medications usage (GLP-1 agonist, insulin, and metformin), and other medication usages (aspirin, ACEI/ARB and statin), SGLT2i users were similarly associated with a lower risk of all-cause death, cardiovascular death, cancer death, and non-cancer, non-vascular death (HR = 0.66 for all-cause death, HR = 0.68 for cardiovascular death, HR = 0.73 for cancer death, and HR = 0.62 for non-cancer, non-vascular death).